[1]武 琪a,陈 亮b,张宝华c.帕金森病患者血清和脑脊液褪黑素水平变化及其临床意义[J].现代检验医学杂志,2017,32(05):90-93.[doi:10.3969/j.issn.1671-7414.2017.05.017]
　WU Qia,CHEN Liangb,ZHANG Bao-huac.Changes and Clinical Significance of Melatonin in Blood and Cerebrospinal Fluid of Patients with Parkinson's Disease[J].Journal of Modern Laboratory Medicine,2017,32(05):90-93.[doi:10.3969/j.issn.1671-7414.2017.05.017]
点击复制

帕金森病患者血清和脑脊液褪黑素水平变化及其临床意义()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第32卷
期数:
2017年05期
页码:
90-93
栏目:
论著
出版日期:
2017-11-02

文章信息/Info

Title:
Changes and Clinical Significance of Melatonin in Blood and Cerebrospinal Fluid of Patients with Parkinson's Disease
文章编号:
1671-7414(2017)05-090-04
作者:
武 琪a; 陈 亮b; 张宝华c
安康市中医医院a.急诊科; b.神经内科; c.质控科,陕西安康 725000
Author(s):
WU Qia; CHEN Liangb; ZHANG Bao-huac
a.Department of Emergency; b.Department of Neurology; c.Department of Medicine Quality Control,Ankang Traditional Chinese Medicine Hospital,Shaanxi Ankang 725000,China
关键词:
帕金森病;  褪黑素;  血清;  脑脊液
分类号:
R745; R446.1
DOI:
10.3969/j.issn.1671-7414.2017.05.017
文献标志码:
A
摘要:
目的 探讨帕金森病(parkinson's,PD)患者血液和脑脊液褪黑素(melatonin,MLT)水平的变化及其临床意义。方法 选择2016年1～12月于安康市中医医院治疗的63例PD患者作为PD组,选择同期非神经系统疾病患者60例作为对照组。采用ELISA法检测所有患者血清和脑脊液MLT水平。结果 对照组患者血清和脑脊液MLT均与年龄呈负相关(r=-0.190,P=0.041; r=-0.208,P=0.017)。PD组患者血清和脑脊液MLT分别为87.3±9.2 pg/ml和338.7±58.6pg/ml,对照组分别为49.5±4.4 pg/ml和232.8±39.7 pg/ml,两组患者血清和脑脊液MLT水平差异均具有统计学意义(t=28.802,P=0.000; t=11.682,P=0.000)。PD组患者血清和脑脊液MLT水平均与病程(r=0.207,P=0.004; r=0.145,P=0.013),UPDRS Ⅱ评分(r=0.187,P=0.013; r=0.192,P=0.007),UPDRS Ⅲ评分(r=0.156,P=0.033; r=0.196,P=0.018)以及H-Y分级(r=0.206,P=0.019; r=0.294,P=0.004)呈正相关。结论 PD患者血清和脑脊液MLT均显著升高,且与患者病程及严重程度呈正相关关系。
Abstract:
Abstract:Objective To investigate the changes of melatonin(MLT)in blood and cerebrospinal fluid(CSF)of Parkinson's disease(PD)patient and its clinical significance.Methods 63 PD patients from January 2016 to December 2016 were recruited to participate in the study as PDgroup.60 patients without nervous system disease were randomly selected in theirhospital in the same period of time as the control group.The concentrations ofMLT in blood and CSF samples were measured and analyzed.Results The serum and CSF levels of MLT in control group was significantly positively related to age(r=-0.190,P=0.041; r=-0.208,P=0.017).The serum and CSF levels of MLT in PD group were significantly higher than those in control group(87.3±9.2 pg/ml vs 49.5±4.4 pg/ml,t=28.802,P=0.000; 338.7±58.6 pg/ml vs 232.8±39.7 pg/ml,t=11.682,P=0.000).Theserum and CSF levels of MLT in PD group both were positively correlated with disease course(r=0.207,P=0.004; r=0.145,P=0.013),UPDRS Ⅱ(r=0.187,P=0.013; r=0.192,P=0.007),UPDRS Ⅲ(r=0.156,P=0.033; r=0.196,P=0.018)and H-Y classification(r=0.206,P=0.019; r=0.294,P=0.004).Conclusion MLT in blood and CSF of PD patients increased significantly.And they both positively correlated with disease course and severity.

参考文献/References:

[1] 张晓艺,毛成洁,陈 怡,等.帕金森病伴疼痛患者临床特征及认知功能研究[J].中华内科杂志,2014,53(1):27-30. Zhang XY,Mao CJ,Chen Y,et al.The clinical characteristics and cognitive function of Parkinson's disease patients associated with pain[J].Chinese Journal of Internal Medicine,2014,53(1):27-30.
[2] Lang AE,Lozano AM.Parkinson's disease[J].Lancet,1998,386(9996):896-912.
[3] Niranjan R.The role of inflammatory and oxidative stress mechanisms in the Pathogenesis of Parkinson's disease:focus on astrocytes[J].Mol Neurobiol,2014,49(1):28-38.
[4] Taylor JM, Main BS, Crack PJ.Neuroinflammation and oxidative stress:co-conspirators in the pathology of Parkinson's disease[J].Neurochem Int,2013,62(5):803-819.
[5] Yildirim FB,Ozsoy O,Tanriover G,et al.Mechanism of the beneficial effect of melatonin in experimental Parkinson's disease[J].Neurochem Int,2014,79(52):1-11.
[6] Breen DP,Nombela C,Vuono R,et al.Hypothalamic volume loss is associated with reduced melatonin output in Parkinson's disease[J].Mov Disord,2016,31(7):1062-1066.
[7] 孟 涛,郑志竑,伍 兵,等.6-羟基多巴胺诱导的帕金森病大鼠眼内褪黑素受体的变化[J].神经解剖学杂志,2015,31(4):403-408. Meng T,Zheng ZH,Wu B,et al.Changes of melatonin receptors in both eyes of 6-hydroxydopamine-induced hemiparkinsonium rats[J].Chinese Journal of Neuroanatomy,2015,31(4):403-408.
[8] 中华医学会神经病学分会运动障碍及帕金森病学组.帕金森病治疗指南[J].中华神经科杂志,2006,39(6):409-412. Parkinson Disease and Movement Disorders Groups of Neurology Branchof Chinese Medical Association.Treatment guideline for Parkinson's disease[J].Chinese Journal of Neurology,2006,39(6):409-412.
[9] Lin L,Meng T,Liu T,et al.Increased melatonin may play dual roles in the striata of a 6-hydroxydopamine model of Parkinson's disease[J].Life Sci,2013,92(4/5):311-316.
[10] Espino J,Rodríguez AB,Pariente JA.The inhibition of TNF-α-induced leucocyte apoptosis by melatonin involves membrane receptor MT1/MT2 interaction[J].J Pineal Res,2013,54(4):442-452.
[11] Singhal NK,Srivastava G,Agrawal S,et al.Melatonin as a neuroprotective agent in the rodent models of parkinson's disease:is it all set to irrefutable clinical translation?[J].Mol Neurobiol,2012,45(1):186-199.
[12] Lin L,Du Y,Yuan S,et al.Serum melatonin is an alternative index of Parkinson's disease severity[J].Brain Res,2014,1547:43-48.

相似文献/References:

[1]武 琪a,张宝华b.Nrf2基因启动子-653G/A,-651G/A和-617C/A位点单核苷酸多态性与帕金森病易感性的关联性研究[J].现代检验医学杂志,2017,32(06):60.[doi:10.3969/j.issn.1671-7414.2017.06.001]
　WU Qia,ZHANG Bao-huab.Association between Nrf2 Gene -653G/A,-651G/A and -617C/A Polymorphism and Susceptibility of Parkinson's Disease[J].Journal of Modern Laboratory Medicine,2017,32(05):60.[doi:10.3969/j.issn.1671-7414.2017.06.001]
[2]李泽东,詹　贞,刘　忆,等.帕金森病患者血清鳞状细胞癌抗原（SCC-Ag）表达的临床意义[J].现代检验医学杂志,2019,34(06):70.[doi:10.3969 ／ j.issn.1671-7414.2019.06.017]
　LI Ze-dong,ZHAN Zhen,LIU Yi,et al.Significance of SCC Antigen Expression in Parkinson’s Disease[J].Journal of Modern Laboratory Medicine,2019,34(05):70.[doi:10.3969 ／ j.issn.1671-7414.2019.06.017]
[3]尚天明,毕开湘.唾液 α- 突触核蛋白 (SNCA) 与嗅觉评估在帕金森病早期筛查中的应用研究[J].现代检验医学杂志,2020,35(06):95.[doi:doi:10.3969/j.issn.1671-7414.2020.06.023]
　SHANG Tian-ming,BI Kai-xiang.Application Research of Olfactory Assessment and Salivary SNCA in EarlyScreening of Parkinson’s Disease[J].Journal of Modern Laboratory Medicine,2020,35(05):95.[doi:doi:10.3969/j.issn.1671-7414.2020.06.023]
[4]李群英,甄时建,何树光,等.帕金森病患者治疗期间血清miR-153，miR-128b水平表达与非运动症状的相关性研究[J].现代检验医学杂志,2021,36(05):120.[doi:10.3969/j.issn.1671-7414.2021.05.027]
　LI Qun-ying,ZHEN Shi-jian,HE Shu-guang,et al.Research on Correlation between Expression of Serum miR-153, miR-128bLevels and Non-motor Symptoms in Patients with Parkinson’s DiseaseDuring Treatment Period[J].Journal of Modern Laboratory Medicine,2021,36(05):120.[doi:10.3969/j.issn.1671-7414.2021.05.027]
[5]闫　欣,商素亮,李　娜,等.血浆S1P和HDL-C表达水平与帕金森病患者临床症状的相关性研究[J].现代检验医学杂志,2022,37(03):182.[doi:10.3969/j.issn.1671-7414.2022.03.038]
　YAN Xin,SHANG Su-liang,LI Na,et al.Correlation between Plasma S1P, HDL-C Expressions Levels and Clinical Symptoms in Patients with Parkinson’s Disease[J].Journal of Modern Laboratory Medicine,2022,37(05):182.[doi:10.3969/j.issn.1671-7414.2022.03.038]
[6]白 雪,董巧云,赵 丽,等.帕金森病患者血清miR-7 和α-Syn 表达水平与认知功能障碍的相关性研究[J].现代检验医学杂志,2023,38(04):78.[doi:10.3969/j.issn.1671-7414.2023.04.014]
　BAI Xue,DONG Qiaoyun,ZHAO Li,et al.Correlation between Serum miR-7 and α-Syn Expression Levels and Cognitive Impairment in Patients with Parkinson’s Disease[J].Journal of Modern Laboratory Medicine,2023,38(05):78.[doi:10.3969/j.issn.1671-7414.2023.04.014]
[7]郑德泉,江 华,林锦标,等.帕金森病患者血清NPASDP-4，MBP 水平表达与认知功能障碍及严重程度的诊断价值研究[J].现代检验医学杂志,2024,39(03):17.[doi:10.3969/j.issn.1671-7414.2024.03.003]
　ZHENG Dequan,JIANG Hua,LIN Jinbiao,et al.Study on the Diagnostic Value of Serum NPASDP-4 and MBP Level Expression with Cognitive Dysfunction and Severity in Parkinson’s Disease Patients[J].Journal of Modern Laboratory Medicine,2024,39(05):17.[doi:10.3969/j.issn.1671-7414.2024.03.003]
[8]牛荣荣,宋世雄,宋 蕾.帕金森病患者血清FGF22 和CXCL16 水平检测对认知障碍的诊断价值[J].现代检验医学杂志,2024,39(03):152.[doi:10.3969/j.issn.1671-7414.2024.03.026]
　NIU Rongrong,SONG Shixiong,SONG Lei.Diagnostic Value of Serum FGF22 and CXCL16 Levels in Patients with Parkinson’s Disease for Cognitive Impairment[J].Journal of Modern Laboratory Medicine,2024,39(05):152.[doi:10.3969/j.issn.1671-7414.2024.03.026]
[9]曹明月,王 巍,周美宁.LPIN1/PPARA 通过抑制SLC47A1 介导的神经元铁死亡缓解帕金森病模型大鼠病情进展的机制研究[J].现代检验医学杂志,2024,39(04):63.[doi:10.3969/j.issn.1671-7414.2024.04.012]
　CAO Mingyue,WANG Wei,ZHOU Meining.Mechanism Study on LPIN1/PPARA Alleviating the Progression of Parkinson’s Disease in Rats by Inhibiting SLC47A1-Mediated Ferroptosis of Neurons[J].Journal of Modern Laboratory Medicine,2024,39(05):63.[doi:10.3969/j.issn.1671-7414.2024.04.012]

备注/Memo

备注/Memo:
作者简介:武 琪(1975-),男,主治医师,研究方向:急诊神经内科,E-mail:wuqi197510@126.com。 通讯作者:张宝华(1977-),E-mail:akszyyy@163.com。
更新日期/Last Update: 1900-01-01